ArticleJournal of molecular neuroscience : MN2026
Mendelian Randomization Analysis of the Brain, Cerebrospinal Fluid, and Plasma Proteome Identifies a Potential Peripheral Biomarker for Isolated REM Sleep Behavior Disorder.
Article in Journal of molecular neuroscience : MN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundIsolated REM sleep behavior disorder (iRBD) is among the strongest clinical markers of prodromal α-synucleinopathies. Pinpointing causal proteins may open the door to early diagnosis and disease-modifying therapies.
methodsWe performed a proteome-wide Mendelian randomization (MR) using protein QTLs from brain, cerebrospinal fluid, and plasma, with GWAS data from 1,061 iRBD cases and 8,386 controls. The findings were validated in an independent cohort of 35,559 individuals from Iceland, utilizing plasma proteome data. To assess the directionality and robustness of the association, we additionally performed Steiger filtering and Bayesian colocalization analyses. PheWAS was applied to explore pleiotropy and safety.
resultsAmong hundreds of proteins screened, only plasma SPOCK3 (SPARC/Osteonectin, Cwcv and Kazal-like Domains Proteoglycan 3) showed a significant causal link to iRBD (OR = 2.07, 95% CI = 1.50-2.84, P = 7.45 × 10⁻⁶). No brain or CSF proteins met significance. In the independent cohort, MR confirmed the association between SPOCK3 and iRBD risk (OR = 1.39, 95% CI: 1.03-1.88, P = 0.029). Steiger filtering supported the inferred causal direction (P < 0.05), and colocalization analysis revealed a high posterior probability of a shared causal variant between SPOCK3 levels and iRBD risk (PPH4 = 0.96). PheWAS revealed no major off-target associations.
conclusionsPlasma SPOCK3 emerges as a candidate peripheral biomarker for iRBD. While Mendelian randomization supports a potential causal association, the underlying mechanisms-such as extracellular matrix involvement-require further experimental validation.
Indexed as
Identifiers
41498878What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.